Modalis Therapeutics has been awarded a rare paediatric disease designation by the US Food and Drug Administration (FDA) for ...

Valerio Therapeutics, a developer of DNA Decoy therapeutics, has announced its acquisition of Emglev Therapeutics, a company ...

PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in ...

LEO Pharma has submitted a New Drug Application (NDA) to China's National Medical Products Administration for Enstilar, ...

Medidata is a winner in the Innovation, and Product Launches categories in the 2024 Pharmaceutical Technology Excellence ...

The MediLedger Project utilises blockchain technology to tackle counterfeit drugs. The project uses blockchain to track and ...

The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 ...

The FDA has approved the first treatment for schizophrenia that targets cholinergic receptors rather than dopamine receptors.

UNICEF has reached an agreement with mpox vaccine manufacturer Bavarian Nordic to supply one million doses of the shot for ...

The US FDA placed a full clinical hold on two diabetes trials for Biomea’s menin inhibitor after reports of liver toxicity.

The collaboration aims to utilise Tempus’ real-world data and biological modelling to enhance the development of Takeda’s ...

Phare Bio has received up to $27m from the Advanced Research Projects Agency for Health (ARPA-H) to advance its drug ...